Looking ahead, integrating functional genomics, multiomics profiling, maturation and differentiation status, and rational drug combinations will be essential for translating mechanistic insights into effective, personalized therapies for highly resistant TP53 mutant AML. Here, TP53 is linked to acute myeloid leukemia.